SecBot SecBot
PRESS-RELEASE ·Filed May 14, 2026

LRMR

Larimar Therapeutics
BULLISH
Impact 7/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

Monitor topline OL data in Q2 2026 and FDA Type B meeting outcome for BLA readiness. The $200.4M cash runway reduces near-term dilution risk.

DirectionBullish
Confidencemedium
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$3.89
T+0 close · May 14, 2026 · via day close
Latest settled
+3.08%
T+60 · $4.01
Vs SPY
−0.50%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 14 $3.89entry
  2. T+1 · 6mo ago −7.97%α −6.74% · $3.58
  3. T+5 · 6mo ago −8.23%α −7.51% · $3.57
  4. T+20 · 5mo ago −10.80%α −9.94% · $3.47
  5. T+60 · 3mo ago +3.08%α −0.50% · $4.01

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Larimar Therapeutics reported Q1 2026 EPS of -$0.31, beating consensus of -$0.57 by 45.6%, with no revenue. The company advanced its BLA for nomlabofusp toward accelerated approval, planning a rolling submission starting June 2026 with topline open-label data expected Q2 2026.

Key Financial Metrics

EPS
−$0.31
est −$0.57 · +45.6%
Rating
strong beat

Key Facts

  • Q1 2026 EPS -$0.31 vs consensus -$0.57 (45.6% beat)
  • Net loss $29.6M vs $29.3M YoY; R&D expenses $25.0M down from $26.6M
  • Cash, cash equivalents and marketable securities $200.4M as of March 31, 2026
  • Planning rolling BLA submission for nomlabofusp starting June 2026; topline OL data expected Q2 2026
  • Breakthrough Therapy Designation granted by FDA in February 2026
  • $115M public offering completed in February 2026, net proceeds $107.6M
  • Projected cash runway into Q2 2027

Financial Impact

EPS beat of 45.6% vs consensus; cash position $200.4M; net loss $29.6M

epscashnet loss

Risk Factors

  • BLA submission and FDA approval are uncertain; regulatory delays or negative feedback could reverse gains
  • No revenue; pre-commercial stage with high cash burn ($29.6M/quarter)

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
94% bullish (17 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3294760

Track record

13 reports on LRMR

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $3.00 Now $3.00 0.00% settles Feb 12
  2. Nov 16, 2026today Press Release Bullish 7/10 Entry $3.10 Now $3.00 −3.23% settles Feb 12
  3. Nov 12, 20264d ago Insider Cluster Bullish 4/10 Entry $3.02 Now $3.00 −0.66% settles Feb 11
  4. Nov 9, 20267d ago 8-K Bullish 7/10 Entry $2.69 Now $3.00 +11.52% settles Feb 8
  5. Nov 5, 202611d ago Press Release Neutral 2/10 Entry $2.39 Now $3.00 +25.52% settles Feb 4
  6. Sep 29, 20266w ago Press Release Neutral 3/10 Entry $3.20 Now $3.00 −6.10% settles Dec 24
  7. Sep 22, 20267w ago Institutional Cluster Bearish 4/10 Entry $3.82 Now $3.00 +21.47% settles Dec 16
  8. May 14, 202626w ago 8-K Bullish 7/10 No price data
  9. May 14, 202626w ago Press Release Bullish 7/10 Viewing Entry $3.89 to $4.01 Now $3.00 −22.88% ▲ +3.08% −0.50% vs SPY
  10. Mar 19, 202634w ago Press Release Mixed 7/10 Entry $4.47 to $3.59 Now $3.00 −32.89% ▼ −19.69% −34.03% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 14, 2026